Epidemiological and experimental evidence exists to suggest that aspirin may possess anti-cancer properties in brain cancer, including glioblastoma multiforme (GBM). The aim of this study was to evaluate the effect of clinically relevant aspirin concentrations on the viability and proliferation of glioblastoma cells in order to establish the role aspirin may have as a potential therapeutic/preventative agent in GBM. PrestoBlue reagent was used to determine the viability of U-87 MG glioblastoma cells and SVG p12 astroglia cells over 7 days following aspirin treatment. CFDA-SE reagent was used to determine the effect of aspirin on U-87 MG cell proliferation over 72 hours. Aspirin did not appear to have a statistically significant effect on U-87 MG or SVG p12 cell viability over 7 days, although trends of reduced viability were seen at day 5 and 7 post drug treatment. Aspirin did not have an inhibitory effect on U-87 MG cell proliferation at 24 and 48 hours post drug treatment, although a slight effect of reduced proliferation was seen at 72 hours post drug treatment. Although further clinically relevant research still needs to take place, along with confirming aspirin’s anti-cancer mechanisms, it is likely that low dose, long term aspirin use could have a future role in preventing GBM, or as an adjuvant therapeutic agent in GBM.
Keywords – Cancer, Glioblastoma Multiforme, Aspirin, Brain Tumour, Glioma, Proliferation, Viability
- There are currently no refbacks.
Copyright © 2014 University of Central Lancashire